Search results
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?
Zacks via Yahoo Finance· 2 years agoAbiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat...
Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$292?
Simply Wall St. via Yahoo Finance· 2 years agoToday we're going to take a look at the well-established Abiomed, Inc. (NASDAQ:ABMD). The company's...
Abiomed (ABMD) Beats Q2 Earnings Estimates
Zacks via Yahoo Finance· 2 years agoAbiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold...
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
Zacks via Yahoo Finance· 2 years agoAbiomed, Inc. ABMD delivered adjusted earnings per share (EPS) of $1.30 in the second quarter of...
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoAbiomed, Inc. ABMD is scheduled to report first-quarter fiscal 2023 results on Aug 4, before market...
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
Zacks via Yahoo Finance· 2 years agoAbiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI...
Abiomed (ABMD) is a Top-Ranked Momentum Stock: Should You Buy?
Zacks via Yahoo Finance· 2 years agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
Can Abiomed (ABMD) Keep the Earnings Surprise Streak Alive?
Zacks via Yahoo Finance· 2 years agoAbiomed (ABMD) has an impressive earnings surprise history and currently possesses the right...
Abiomed, Inc. (NASDAQ:ABMD) Stock Has Shown Weakness Lately But Financials Look Strong: Should...
Simply Wall St. via Yahoo Finance· 2 years agoWith its stock down 7.1% over the past three months, it is easy to disregard Abiomed (NASDAQ:ABMD)....
Abiomed's (ABMD) Impella Favored by Latest Study Result
Zacks via Yahoo Finance· 2 years agoAbiomed, Inc. ABMD has recently announced favorable results from the Restore EF study, which was...
